Details for Patent: 11,583,526
✉ Email this page to a colleague
Which drugs does patent 11,583,526 protect, and when does it expire?
Patent 11,583,526 protects ORGOVYX and is included in one NDA.
This patent has sixty-two patent family members in twenty-four countries.
Drugs Protected by US Patent 11,583,526
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sumitomo Pharma | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,583,526
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 109759 | ⤷ Subscribe | |||
Argentina | 109762 | ⤷ Subscribe | |||
Argentina | 110636 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |